Lecanemab is under clinical development by Eisai and currently in the Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lecanemab’s likelihood of approval (LoA) and phase transition for Alzheimer’s Disease took place on 07 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lecanemab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lecanemab overview

Lecanemab (BAN-2401) is under development for the treatment of Down syndrome, traumatic brain injury, Alzheimer's disease and mild cognitive impairment (MCI) due to Alzheimer's disease (AD). The drug candidate is administered as an intravenous and subcutaneous infusions as a solution. Lecanemab (BAN2401) is the humanized mAb158 derived from mice immunized with protofibrils derived from the arctic mutation of Abeta42.

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Quick View Lecanemab LOA Data

Report Segments
  • Innovator
Drug Name
  • Lecanemab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Developers
  • Sponsor Company: Eisai
  • Originator: BioArctic
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.